NL-OMON47906已完成4 期
Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands - Third MMR vaccine dose in young adults (acronym: MMR-3)
RIVM0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy young adult 18-25 years of age., Previously been immunized with two
- •doses of the MMR vaccine according to the Dutch NIP (MMR-1 at ~14 months and
- •MMR-2 at ~9 years).
排除标准
- •Medical conditions that will severely affect immunological responses to
- •vaccinations, such as, but not limited to, cancer or an immune disorder.,
- •Vaccination should be postponed during any illness with fever >38.5°C until the
- •fever has disappeared., Vaccination with any vaccine during the first two weeks
- •before and four weeks after MMR-3., An additional MMR vaccination during the
- •study., Coagulation disorder and/or anticoagulant medication. , Be or have been
- •under immunosuppressive medical treatment, like cytostatics, high-dose
- •corticosteroids, immune globulins, blood or plasma transfusions that might
- •interfere with the results of the study (within the previous 3 months)., Have
- •or previously had clinical symptoms of mumps virus infection., Have or
- •previously had cases of mumps disease within your Household., Had experienced a
- •previous severe adverse reaction to any vaccine. , Being pregnant; Furthermore,
- •pregnancy should be avoided for 1 month following vaccination. , Breast-feeding
研究者
相似试验
已完成
不适用
A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulinesNL-OMON51004Erasmus MC, Universitair Medisch Centrum Rotterdam44
已完成
2 期
A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levelsdyslipidemiaabnormal cholesterol values10013317NL-OMON40373Kowa Research Europe52
已完成
3 期
A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension period in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatmentDiabetes mellitus type 210018424diabetesNL-OMON38357Boehringer Ingelheim18
已完成
3 期
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infantsNL-OMON49743Pfizer14
已完成
3 期
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)pancreatic canceradenocarcinoma of the pancreas10015674NL-OMON41730Incyte Corporation12